Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna’s Native Complex Platform™ is the engine that will make this happen, moving ideas for disease-modifying therapies from possibility to reality.

Septerna has assembled a team that thrives on innovation, combining pioneering GPCR scientists with experienced drug hunters. Our founders have made seminal discoveries that reveal the inner workings of GPCRs and how they control physiology. Our scientists have built upon these unique insights to develop our industrial-scale Native Complex Platform™.

We are focusing the Native Complex Platform™ on tackling previously difficult-to-drug GPCR targets, and our small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. With an unprecedented level of productivity, we are setting the stage for a new future for GPCR-targeted medicines.

Septerna pipeline Oral PTHR1 receptor - We are working on oral replacements for injectable GPCR peptide drugs